1 / 1

JUPITER

JUPITER. Rosuvastatin associated with a significant ↓ in the primary outcome of MI, stroke, unstable angina, revascularization, or cardiovascular death ( HR 0.56, 95% CI 0.46-0.69, p < 0.00001) All-cause mortality ↓ with rosuvastatin (p = 0.02) Serious adverse effects were similar (p = 0.60).

elsa
Download Presentation

JUPITER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. JUPITER Rosuvastatin associated with a significant ↓ in the primary outcome of MI, stroke, unstable angina, revascularization, or cardiovascular death (HR 0.56, 95% CI 0.46-0.69, p < 0.00001) All-cause mortality ↓ with rosuvastatin (p = 0.02) Serious adverse effects were similar (p = 0.60) (p = 0.02) (p < 0.00001) Placebo (n = 8,901) Rosuvastatin (n = 8,901) Trial design: Apparently healthy patients with LDL cholesterol <130 mg/dl and hs-CRP ≥2 mg/L were randomized to rosuvastatin 20 mg daily or placebo. Clinical outcomes were compared at a median of 1.9 years. Results 2 2 1.36 1.25 Events/100 person-years Events/100 person-years 1.0 Conclusions 1 1 0.77 • Rosuvastatin was associated with a significant reduction in major cardiovascular events, including death, in patients with LDL <130 mg/dl, but high hs-CRP (≥2.0 mg/L) • May require revision of current guidelines 0 0 Primary outcome All-cause mortality Ridker PM, et al. NEJM 2008;359:2195-207 Presented by Dr. Paul Ridker at AHA 2008

More Related